Stem-cell fate can be influenced by metabolite levels in culture, but it is not known whether physiological variations in metabolite levels in normal tissues regulate stem-cell function in vivo. Here we describe a metabolomics method for the analysis of rare cell populations isolated directly from tissues and use it to compare mouse haematopoietic stem cells (HSCs) to restricted haematopoietic progenitors. Each haematopoietic cell type had a distinct metabolic signature. Human and mouse HSCs had unusually high levels of ascorbate, which decreased with differentiation. Systemic ascorbate depletion in mice increased HSC frequency and function, in part by reducing the function of Tet2, a dioxygenase tumour suppressor. Ascorbate depletion cooperated with Flt3 internal tandem duplication (Flt3ITD) leukaemic mutations to accelerate leukaemogenesis, through cell-autonomous and possibly non-cell-autonomous mechanisms, in a manner that was reversed by dietary ascorbate. Ascorbate acted cell-autonomously to negatively regulate HSC function and myelopoiesis through Tet2-dependent and Tet2-independent mechanisms. Ascorbate therefore accumulates within HSCs to promote Tet activity in vivo, limiting HSC frequency and suppressing leukaemogenesis.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Garaycoechea, J. I. et al. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 489, 571–575 (2012)
Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009)
Mihaylova, M. M., Sabatini, D. M. & Yilmaz, O. H. Dietary and metabolic control of stem cell function in physiology and cancer. Cell Stem Cell 14, 292–305 (2014)
Zhang, H. et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352, 1436–1443 (2016)
Agathocleous, M. et al. Metabolic differentiation in the embryonic retina. Nat. Cell Biol. 14, 859–864 (2012)
Wang, J. et al. Dependence of mouse embryonic stem cells on threonine catabolism. Science 325, 435–439 (2009)
Blaschke, K. et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 500, 222–226 (2013)
Carey, B. W., Finley, L. W., Cross, J. R., Allis, C. D. & Thompson, C. B. Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518, 413–416 (2015)
Naka, K. et al. Dipeptide species regulate p38MAPK–Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nat. Commun. 6, 8039 (2015)
Takubo, K. et al. Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell 12, 49–61 (2013)
Simsek, T. et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 7, 380–390 (2010)
May, J. M. The SLC23 family of ascorbate transporters: ensuring that you get and keep your daily dose of vitamin C. Br. J. Pharmacol. 164, 1793–1801 (2011)
Seita, J. et al. Gene Expression Commons: an open platform for absolute gene expression profiling. PLoS ONE 7, e40321 (2012)
Manning, J. et al. Vitamin C promotes maturation of T-cells. Antioxid. Redox Signal. 19, 2054–2067 (2013)
Young, J. I., Züchner, S. & Wang, G. Regulation of the epigenome by vitamin C. Annu. Rev. Nutr. 35, 545–564 (2015)
Wang, T. et al. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell 9, 575–587 (2011)
Kivirikko, K. I., Myllylä, R. & Pihlajaniemi, T. Protein hydroxylation: prolyl 4-hydroxylase, an enzyme with four cosubstrates and a multifunctional subunit. FASEB J. 3, 1609–1617 (1989)
Rebouche, C. J. Ascorbic acid and carnitine biosynthesis. Am. J. Clin. Nutr. 54, 1147S–1152S (1991)
Knowles, H. J., Raval, R. R., Harris, A. L. & Ratcliffe, P. J. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 63, 1764–1768 (2003)
Vukovic, M. et al. Adult hematopoietic stem cells lacking Hif-1α self-renew normally. Blood 127, 2841–2846 (2016)
Yin, R. et al. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J. Am. Chem. Soc. 135, 10396–10403 (2013)
Chen, J. et al. Vitamin C modulates TET1 function during somatic cell reprogramming. Nat. Genet. 45, 1504–1509 (2013)
Minor, E. A., Court, B. L., Young, J. I. & Wang, G. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J. Biol. Chem. 288, 13669–13674 (2013)
Ito, S. et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333, 1300–1303 (2011)
Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009)
Jan, M. et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 4, 149ra118 (2012)
Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11–24 (2011)
Ko, M. et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl Acad. Sci. USA 108, 14566–14571 (2011)
Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25–38 (2011)
Abdel-Wahab, O. et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114, 144–147 (2009)
Shih, A. H. et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27, 502–515 (2015)
Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009)
Schleicher, R. L., Carroll, M. D., Ford, E. S. & Lacher, D. A. Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003–2004 National Health and Nutrition Examination Survey (NHANES). Am. J. Clin. Nutr. 90, 1252–1263 (2009)
Pronier, E. et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 118, 2551–2555 (2011)
Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079–1089 (2012)
Cimmino, L. et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat. Immunol. 16, 653–662 (2015)
An, J. et al. Acute loss of TET function results in aggressive myeloid cancer in mice. Nat. Commun. 6, 10071 (2015)
Loria, C. M., Klag, M. J., Caulfield, L. E. & Whelton, P. K. Vitamin C status and mortality in US adults. Am. J. Clin. Nutr. 72, 139–145 (2000)
Khaw, K. T. et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. Lancet 357, 657–663 (2001)
Liu, M. et al. Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine. Proc. Natl Acad. Sci. USA 113, 10238–10244 (2016)
Huijskens, M. J., Wodzig, W. K., Walczak, M., Germeraad, W. T. & Bos, G. M. Ascorbic acid serum levels are reduced in patients with hematological malignancies. Results Immunol. 6, 8–10 (2016)
Moertel, C. G. et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy—a randomized double-blind comparison. N. Engl. J. Med. 312, 137–141 (1985)
Yun, J. et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350, 1391–1396 (2015)
Chen, Q. et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Natl Acad. Sci. USA 105, 11105–11109 (2008)
Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179–1181 (2012)
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014)
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014)
Maeda, N. et al. Aortic wall damage in mice unable to synthesize ascorbic acid. Proc. Natl Acad. Sci. USA 97, 841–846 (2000)
Lee, B. H. et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 12, 367–380 (2007)
Sotiriou, S. et al. Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat. Med. 8, 514–517 (2002)
Kühn, R., Schwenk, F., Aguet, M. & Rajewsky, K. Inducible gene targeting in mice. Science 269, 1427–1429 (1995)
Washko, P. W., Welch, R. W., Dhariwal, K. R., Wang, Y. & Levine, M. Ascorbic acid and dehydroascorbic acid analyses in biological samples. Anal. Biochem. 204, 1–14 (1992)
Mullen, A. R. et al. Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Reports 7, 1679–1690 (2014)
Xia, J., Sinelnikov, I. V., Han, B. & Wishart, D. S. MetaboAnalyst 3.0—making metabolomics more meaningful. Nucleic Acids Res. 43, W251–W257 (2015)
Doulatov, S. et al. Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat. Immunol. 11, 585–593 (2010)
Kogan, S. C. et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100, 238–245 (2002)
Noguchi, K., Gel, Y. R., Brunner, E. & Konietschke, F. NparLD: an R software package for the nonparametric analysis of longitudinal data in factorial experiments. J. Stat. Softw. 50, 1–23 (2012)
Acar, M. et al. Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal. Nature 526, 126–130 (2015)
S.J.M. is a Howard Hughes Medical Institute (HHMI) Investigator, the Mary McDermott Cook Chair in Pediatric Genetics, the Kathryn and Gene Bishop Distinguished Chair in Pediatric Research, the director of the Hamon Laboratory for Stem Cells and Cancer, and a Cancer Prevention and Research Institute of Texas Scholar. M.A. was a Royal Commission for the Exhibition of 1851 Research Fellow. We thank F. Harrison for sharing the Slc23a2−/− mice, N. Loof and the Moody Foundation Flow Cytometry Facility for flow cytometry, K. Correll, A. Leach and A. Gross for mouse colony management and BioHPC at UT Southwestern for providing high-performance computing. This work was supported by the Cancer Prevention and Research Institute of Texas and the National Institutes of Health (R37 AG024945 and R01 DK100848).
The authors declare no competing financial interests.
Reviewer Information Nature thanks H. Christofk, R. Levine and the other anonymous reviewer(s) for their contribution to the peer review of this work.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
a, Diagram of the isolation procedure. b–f, Fold changes in the levels of representative metabolites in 20,000 bone marrow cells before and after each step of the cell isolation procedure. Metabolites were extracted before and after bone marrow cells were kept on ice for 7 h (b), centrifuged at 4 °C at 300g for 5 min (c), stained with the antibodies used for HSC isolation (d), cells underwent positive selection with anti-CD45 and anti-Ter119 beads (e) or were sorted by flow cytometry for CD45 and Ter119 (f). G1P, glucose/fructose-1-phosphate; GPC, glycerophosphocholine; GSH, glutathione; NAD, nicotinamide adenine dinucleotide; SAM, S-adenosylmethionine; SMTA, S-methyl-5′-thioadenosine. Although most bone marrow cells are CD45+ or Ter119+, unfractionated samples are different in cellular composition from samples after selection and sorting, perhaps contributing to the changes observed in some metabolites in e and f. Data were normalized to the median metabolite signal intensity of each sample. Statistical significance was assessed with t-tests performed on log2-transformed data. We accounted for multiple comparisons by controlling the false discovery rate. n = 3 mice; *P < 0.05, **P < 0.01, ***P < 0.001. g, Ascorbate levels were compared in whole bone marrow cells from which metabolites were extracted before the cell purification procedure, or after flow cytometric purification (a total of n = 4 mice from two independent experiments). Statistical significance was assessed using a paired t-test. All data represent mean ± s.d. ns, not significant. Source data
Extended Data Figure 2 Differences in metabolite levels among haematopoietic stem and progenitor cell populations in the bone marrow.
a, Types of metabolites detected in 10,000 HSCs. b, Unsupervised clustering of metabolomic data from HSCs, MPPs and CD45+ bone marrow haematopoietic cells isolated from six independent experiments. BM, bone marrow. c, Metabolites that significantly differed between HSCs and CD45+ bone marrow cells (six independent experiments with a total of 6 HSC samples and 16 CD45+ bone marrow samples). GSH, glutathione; IMP, inosine monophosphate. Statistical significance was assessed using t-tests performed on log2-transformed data. We accounted for multiple comparisons by controlling the false discovery rate. All data represent mean ± s.d. d, The metabolites that we measured in stem and progenitor cell populations. The display is autoscaled for each metabolite to illustrate changes across samples. In total, 52 out of 64 metabolites show statistically significant changes among at least some cell populations (one experiment is shown, representative of three independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001) assessed using a one-way ANOVA for each metabolite followed by Fisher’s LSD tests corrected for multiple comparisons by controlling the false discovery rate. Source data
Extended Data Figure 3 The ascorbate content in haematopoietic stem and progenitor cells correlates with ascorbate transporter expression level and the phenotype of ascorbate-depleted Gulo−/− mice.
a, Ascorbate content versus slc23a2 expression in haematopoietic stem and progenitor cell populations. The plotted data are from Fig. 1c, d. b–s, u, Analysis of ascorbate-depleted Gulo−/− mice and littermate controls (a total of n = 5–11 mice per genotype per time point were analysed from 3–6 independent experiments per time point). t, The percentage of cells that incorporated a three-day pulse of 5-bromodeoxyuridine (BrdU) at 7–8 weeks of age (a total of n = 4–6 mice per genotype from three independent experiments). Statistical significance was assessed with a two-way ANOVA followed by Fisher’s LSD tests (b–l) or Mann–Whitney U-tests (p, u). We corrected for multiple comparisons by controlling the false discovery rate. *P < 0.05, **P < 0.01, ***P < 0.001. All data represent mean ± s.d. Source data
Extended Data Figure 4 Ascorbate depletion did not have any detectable effects on global histone methylation, collagen levels, ROS levels, carnitine metabolism or Tet1–Tet3 expression in HSCs or other haematopoietic progenitors.
a, Western blots with antibodies against the indicated histone modifications were performed using haematopoietic cells from eight-week-old ascorbate-depleted Gulo−/− mice and littermate controls (a total of n = 3–6 mice per genotype from three independent experiments). Bar graphs show band intensity relative to the band intensity of the wild-type sample of each cell type. We did not observe an increase in histone methylation for any of the modifications, as would be expected if ascorbate was promoting global histone demethylase activity. We observed reduced H3K27me3 in HPCs (note that the data in Fig. 3e show that the effects of ascorbate depletion on Flt3ITD-driven myelopoiesis were mediated mainly by reduced Tet2 function). For gel source data, see Supplementary Fig. 1. MyP, myeloid progenitor; WBM, whole bone marrow. b, Histochemical staining of collagen with Sirius red (bright field or polarized light) or Masson’s trichrome (blue) of bone sections from 8–16-week-old Gulo−/− mice and littermate controls (photographs are representative of 6–8 mice per genotype from two independent experiments). c, Carnitine and acetylcarnitine levels were measured by LC–MS/MS for the indicated cell populations obtained from 7–8-week-old Gulo−/− and littermate-control mice (a total of n = 4–7 mice per genotype from four independent experiments). Data show carnitine/acetylcarnitine levels relative to the average levels in wild-type whole bone marrow samples. d, ROS levels were measured in 12-week-old Gulo−/− and littermate-control mice using CellRox Deep Red and Enzo Total ROS dyes (a total of n = 3–4 mice per genotype from three independent experiments). Data show ROS levels relative to wild-type whole bone marrow samples. e, Ascorbate levels were measured in the plasma and bone marrow (BM) of 4–6-month-old Gulo−/− mice or controls (a total of n = 12–17 mice per genotype for plasma and n = 5 mice per genotype for bone marrow were analysed from three independent experiments). f, Tet1–Tet3 transcript levels did not change in Gulo−/− versus littermate control mice, suggesting that the effect of ascorbate depletion on Tet activity was not due to reduced Tet1–Tet3 transcription (n = 3 mice). Statistical significance was assessed with two-way ANOVAs (a-d, f) followed by Fisher’s LSD tests or Welch’s tests (e), or Mann–Whitney test (a- H3K36me2-HPC). We corrected for multiple comparisons by controlling the false discovery rate. All data represent mean ± s.d. Source data
a–g, Mx1-Cre;Tet2fl/fl mice and littermate controls (+/+) were injected with poly(I:C) at 6–8 weeks of age. The frequencies of HSCs and other haematopoietic progenitors were analysed three weeks later (a total of n = 10–24 mice per genotype from 9–14 independent experiments). h, Percentage of donor-derived haematopoietic cells after competitive transplantation of 200,000 donor Tet2+/+, or Tet2Δ/+ or Tet2Δ/Δ bone marrow cells along with 500,000 wild-type recipient competitor cells in irradiated recipient mice (a total of five donors and 15–25 recipients per treatment from five independent experiments). All data represent mean ± s.d. Statistical significance was assessed with Kruskal–Wallis tests (a–g), or a non-parametric mixed model followed by a Kruskal–Wallis test for individual time points (h). We corrected for multiple comparisons by controlling the false discovery rate. *P < 0.05, **P < 0.01, ***P < 0.001. Source data
a, Ascorbate levels in sorted cell populations from transplanted recipient mice (a total of n = 2–4 mice per genotype from two independent experiments). b, Percentage of donor cells that are myeloid, B or T cells in wild-type or Gulo−/− recipients 16 weeks after transplantation (a total of n = 13–18 mice per condition were analysed from four independent experiments). c, d, Competitive transplantation of 500,000 donor bone marrow cells from Tet2fl/fl;Mx1-cre mice or littermate controls along with 1,500,000 competitor wild-type cells in irradiated wild-type (ascorbate-replete) or Gulo−/− (ascorbate-depleted) mice (a total of two donor mice and 5–10 recipient mice per treatment from two independent experiments). e, Plasma ascorbate levels in wild-type mice, Gulo−/− mice or Gulo−/− mice fed an ascorbate-supplemented diet (a total of n = 6–17 mice per condition were analysed from four independent experiments). f, Ascorbate content in bone marrow cells from wild-type and Gulo−/− mice fed normal mouse chow or an ascorbate-supplemented diet (a total of n = 3–11 mice per condition were analysed from three independent experiments). g–m, Myeloid and erythroid differentiation were assessed eight days after culturing HSCs in the presence or absence of ascorbate or its more stable derivative, 2-phospho-ascorbate (a total of n = 48 wells for myeloid and 24 wells for erythroid differentiation from two independent experiments). All data represent mean ± s.d. Statistical significance was assessed with Welch’s tests (a, b), Kruskal–Wallis tests (e–m), or a non-parametric mixed model followed by a Kruskal–Wallis test for individual time points (d). We corrected for multiple comparisons by controlling the false discovery rate. *P < 0.05, **P < 0.01, ***P < 0.001. Source data
Extended Data Figure 7 Gene expression changes in HSCs/MPPs from Gulo−/−, Tet2Δ/Δ and Tet2Δ/Δ;Gulo−/− mice relative to control HSCs/MPPs.
a–c, HSCs/MPPs were isolated from 4–5-month-old mice of the indicated genotypes. Mice from all treatments were maintained on low ascorbate water and treated with poly(I:C) to induce Tet2 deletion by Mx1-Cre two months before HSC/MPP isolation. a, Fold-change values for all genes that significantly differed among any combination of genotypes (DESeq2 likelihood ratio tests for differential expression, corrected for multiple comparisons by controlling the false discovery rate). The value for each gene in the control cells was set to one. Red and green indicate increases and decreases in gene expression, respectively. The number of genes in Gulo−/− and Tet2Δ/Δ HSCs/MPPs that changed in expression in the same direction in both genotypes relative to control HSCs/MPPs was significantly higher than would be expected by chance (P = 0.01, binomial test). b, Fold change (log2) for HSCs/MPPs of each genotype relative to control HSCs/MPPs. All genes that changed in the same direction in all three genotypes relative to control are shown and for which the log2 fold change was >0.7 or <−0.7 and fragments per kilobase of transcript per million mapped reads (FPKM) > 1. Negative fold change values indicate that the expression of the indicated gene decreased in the indicated genotypes compared to control and positive values indicate that the expression of the gene increased. c, Gene set enrichment analysis showed that of the top 20 gene sets (based on normalized enrichment score) that were downregulated in Gulo−/− compared to control HSCs/MPPs, 4 were also among the top 20 gene sets downregulated in Tet2Δ/Δ compared to control HSCs/MPPs (n = 3 mice per genotype, except for the Tet2Δ/Δ treatment, for which n = 2). Source data
Extended Data Figure 8 Collaboration between Flt3ITD and either Tet2 deficiency or ascorbate depletion.
a–f, Analysis of the frequencies of haematopoietic stem and progenitor cell populations in the bone marrow of 10–12-week-old Mx1-Cre;Tet2fl/fl;Flt3ITD mice and littermate controls three weeks after poly(I:C) treatment (12–17 independent experiments; the numbers of mice per treatment in a–c are shown across the top of a and for d–f across the top of d). g, Percentage of donor-derived haematopoietic cells after competitive transplantation of 300,000 donor bone marrow cells of the indicated genotypes along with 300,000 competing recipient cells in irradiated recipient mice (a total of 2–5 donor mice and 6–20 recipient mice per treatment from five independent experiments). h, Secondary transplantation of 5 million bone marrow cells from primary Gulo−/− (ascorbate-depleted) recipients of Flt3ITD/+ cells in irradiated wild-type or ascorbate-depleted Gulo−/− recipient mice (a total of three donor mice and 10–18 recipient mice per treatment from three independent experiments). *Comparison to wild type and #comparison to Flt3ITD/+. i, Ascorbate levels in donor cells of the indicated genotypes sorted from transplant recipients (a total of n = 4 mice per condition from 2 independent experiments). 1°, primary transplantation; 2°, secondary transplantation. j, Frequencies of donor cells of the indicated genotypes in the blood of transplant recipients described in Fig. 3f, g. k, Analysis of HSC frequency in the fetal liver of embryonic day (E)17.5 mice of the indicated genotypes (five independent experiments; the numbers of mice per treatment are shown across the top). All data represent mean ± s.d. Statistical significance was assessed with one-way ANOVAs followed by Fisher’s LSD tests (d, k) or Kruskal–Wallis tests (a–c, e). In other cases, we used two-way ANOVAs followed by Fisher’s LSD tests (i), Kruskal–Wallis tests (j) or a non-parametric mixed model followed by Kruskal–Wallis tests for individual time points (g, h). We corrected for multiple comparisons by controlling the false discovery rate. *P < 0.05, **P < 0.01, ***P < 0.001; #P < 0.05, ##P < 0.01, ###P < 0.001; +P < 0.05, ++P < 0.01, +++P < 0.001. *Comparison to the wild-type (+/+) condition, #comparison to the Flt3ITD condition and +comparison to the Tet2Δ/+ or Tet2Δ/Δ conditions. To simplify the representation of statistical significance in g, statistical significance was only noted when both Tet2Δ/+ and Tet2Δ/Δ conditions, or both Tet2Δ/+;Flt3ITD and Tet2Δ/Δ;Flt3ITD conditions, were significantly different from other conditions). Source data
a–g, Analysis of recipient mice described in Fig. 4a–d. Statistical significance was assessed with one-way ANOVAs followed by Fisher’s LSD tests (f, g) or Kruskal–Wallis tests (e). d, Representative images from the experiments quantified in Fig. 4a. All data represent mean ± s.d. We corrected for multiple comparisons by controlling the false discovery rate. *P < 0.05, **P < 0.01, ***P < 0.001.
a, b, Analysis of recipient mice described in Fig. 4e–j. Statistical significance was assessed with one-way ANOVAs followed by Fisher’s LSD tests (b) or Kruskal–Wallis tests (a). c, Western blots with antibodies against the indicated histone modifications were performed using protein extracted from Tet2Δ/+;Flt3ITD/+ leukaemia cells isolated by flow cytometry from wild-type or ascorbate-depleted Gulo−/− transplant recipients (results are representative of two independent experiments). d, Diff-Quik-stained blood smears from Gulo−/− recipients of Tet2Δ/+;Flt3ITD/+ cells fed with an ascorbate-supplemented diet before and after the engraftment of leukaemia cells (representative images from the experiments described in Fig. 5a and quantified in Fig. 5c). Cells with an immature blast-like morphology were more abundant in the blood of ascorbate-depleted Gulo−/− recipients compared to ascorbate-fed Gulo−/− recipients. e, f, WBCs in recipient mice from the experiment described in Fig. 5a. The statistical significance of differences among treatments was assessed with Kruskal–Wallis tests (a, e, f) or a one-way ANOVA (b) or a two-way ANOVA followed by Fisher’s LSD tests (c). All data represent mean ± s.d. We corrected for multiple comparisons by controlling the false discovery rate. *P < 0.05, **P < 0.01, ***P < 0.001. Source data
About this article
Cite this article
Agathocleous, M., Meacham, C., Burgess, R. et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature 549, 476–481 (2017). https://doi.org/10.1038/nature23876
Communications Biology (2020)
Current Opinion in Genetics & Development (2020)
Experimental Hematology (2020)
MDH1-mediated malate-aspartate NADH shuttle maintains the activity levels of fetal liver hematopoietic stem cells
Nature Cell Biology (2020)